RxDoctor Payments Data

Elizabeth Manley

Gerontology · Yucca Valley, CANPI 1528739398

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 21 payments — averaging $63.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cumberland Pharmaceuticals, Inc.$265
  • GSK$227
  • Regeneron Healthcare Solutions, Inc.$183
  • Insmed, Inc.$170
  • Boehringer Ingelheim$145
  • Viatris Specialty LLC$139
  • plus $196 from 4 others

What the payments were for

  • Food & beverage$1,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 75th percentile of 348 gerontology providers in California.

See all gerontology providers in California

Medicare billing

Part B allowed, 2024
$195,622
Medicare patients
293
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$52,234
EliquisApixaban33$35,148
FarxigaDapagliflozin Propanediol34$24,000
JardianceEmpagliflozin21$20,790
VraylarCariprazine Hcl13$17,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,640
TrulicityDulaglutide14$13,158
Breo ElliptaFluticasone/Vilanterol23$12,059
MyrbetriqMirabegron17$7,509
Repatha SureclickEvolocumab12$6,535
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,338
Gabapentin113$3,073
Duloxetine Hcl44$2,842
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,839
Albuterol Sulfate HfaAlbuterol Sulfate58$2,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$227$33,13264 claims
Boehringer IngelheimJardiance$145$20,79021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 348 gerontology providers in California.

Other gerontology in Yucca Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →